Login / Signup

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

Russell M NicholsLisa MacphersonDipak R PatelWendy W YehAmanda Peppercorn
Published in: Infectious diseases and therapy (2024)
ClinicalTrials.gov identifier, NCT04634409.
Keyphrases
  • coronavirus disease
  • sars cov
  • phase iii
  • open label
  • study protocol
  • phase ii
  • clinical trial
  • combination therapy
  • respiratory syndrome coronavirus
  • randomized controlled trial